Summary
A randomized, double-blind, placebo-controlled study of the safety and tolerability of Study Drug and its effects on biomarkers in subjects with coronary artery disease.
Register to download
PRA Strategies Impress Client
You may also be interested in:
page
Cardio-Metabolic
We’ve contributed to the successful approval of eight marketed cardio-metabolic drugs.
Read More
page
Clinical Development
We work hand-in-hand with our sponsors to develop strategic, flexible approaches that leverage Clinical Informatics, state-of-the-art technologies,…
Read More
Blog
Ask the Experts: Insights on NASH and the Current Research and Treatments
NASH (Non-Alcoholic Steatohepatitis) is a rising disease that is sweeping the population. It is a terminal diagnosis that currently requires a liver…
Read Story
View all related content and resources for Cardio-Metabolic
Explore Insights